Retinoic Acid Signalling in Neuropsychiatric Disease: Possible Markers and Treatment Agents

  • Sarah J. Bailey
  • Peter J. McCaffery

Retinoic acid is the transcriptionally active product of vitamin A, potentially controlling expression of several hundred genes through activation of specific nuclear receptors. The retinoic acid receptors (RARs) are expressed through much of the adult brain; in contrast the ligand for these receptors is much more restricted in its extent of expression. Non-liganded RARs likely control function through transcriptional repression whereas ligand activated receptors probably regulate more restricted functions including neuroplasticity and neurogenesis. Deregulation of retinoic acid signalling through application of excess levels of this ligand have been associated with depression while genetic and anatomical evidence has linked retinoic acid with the neurodevelopmental hypothesis of schizophrenia and autism. The RARs frequently act in conjunction with the second class of retinoid receptors, the retinoid X receptors (RXRs). These RXRs heterodimerize with other classes of nuclear receptors, including the thyroid hormone receptor which, like those for retinoic acid, are associated with schizophrenia and depression. It is possible that drugs that act on RXRs may be particularly effective in psychiatric disease by acting simultaneously on several nuclear receptor signalling pathways.


Depression schizophrenia autism RXR nuclear receptor retinoic acid vitamin A serotonin hippocampus neurogenesis dopamine receptor epigenetic 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cannon TD, Keller MC. Endophenotypes in the genetic analyses of mental disorders. Annu Rev Clin Psychol 2006; 2: 267–90.PubMedGoogle Scholar
  2. 2.
    Levinson DF. The genetics of depression: a review. Biol Psychiatry 2006; 60: 84–92.PubMedGoogle Scholar
  3. 3.
    McClellan JM, Susser E, King MC. Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190: 194–9.PubMedGoogle Scholar
  4. 4.
    Hennah W, Thomson P, McQuillin A, et al. DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry 2008. [epub ahead of print].Google Scholar
  5. 5.
    Blackwood DH, Pickard BJ, Thomson PA, et al. Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1. Neurotox Res 2007; 11: 73–83.PubMedGoogle Scholar
  6. 6.
    McClay JL, Fanous A, van den Oord EJ, et al. Catechol-O-methyltransferase and the clinical features of psychosis. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 935–8.Google Scholar
  7. 7.
    Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137–51.PubMedGoogle Scholar
  8. 8.
    Berk M, Dodd S, Kauer-Sant'anna M, et al. Dopamine dys-regulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007: 41–9.Google Scholar
  9. 9.
    Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27: 254–89.PubMedGoogle Scholar
  10. 10.
    Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006; 14: 660–8.PubMedGoogle Scholar
  11. 11.
    Hennah W, Thomson P, Peltonen L, et al. Genes and schizophrenia: beyond schizophrenia: the role of DISC1 in major mental illness. Schizophr Bull 2006; 32: 409–16.PubMedGoogle Scholar
  12. 12.
    Rzhetsky A, Wajngurt D, Park N, et al. Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci USA 2007; 104: 11694–9.PubMedGoogle Scholar
  13. 13.
    Kawaguchi R, Yu J, Honda J, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007; 315: 820–5.PubMedGoogle Scholar
  14. 14.
    Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 2002; 43: 1773–808.PubMedGoogle Scholar
  15. 15.
    McCaffery PJ, Adams J, Maden M, et al. Too much of a good thing: retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. Eur J Neurosci 2003; 18: 457–72.PubMedGoogle Scholar
  16. 16.
    Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol 2005; 75: 275–93.PubMedGoogle Scholar
  17. 17.
    Wagner E, Luo T, Drager UC. Retinoic acid synthesis in the postnatal mouse brain marks distinct developmental stages and functional systems. Cereb Cortex 2002; 12: 1244–53.PubMedGoogle Scholar
  18. 18.
    Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000; 57: 925–35.PubMedGoogle Scholar
  19. 19.
    Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477–501.PubMedGoogle Scholar
  20. 20.
    Bhugra D. The global prevalence of schizophrenia. PLoS Med 2005; 2: e151; quiz e75.PubMedGoogle Scholar
  21. 21.
    Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187–92.PubMedGoogle Scholar
  22. 22.
    Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annu Rev Med 2007; 58: 49–61.PubMedGoogle Scholar
  23. 23.
    Lang UE, Puls I, Muller DJ, et al. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007; 20: 687–702.PubMedGoogle Scholar
  24. 24.
    Susser ES, Lin SP. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944–1945. Arch Gen Psychiatry 1992; 49: 983–8.PubMedGoogle Scholar
  25. 25.
    St Clair D, Xu M, Wang P, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959–1961. JAMA 2005; 294: 557–62.PubMedGoogle Scholar
  26. 26.
    Goodman AB. Congenital anomalies in relatives of schizophrenic probands may indicate a retinoid pathology. Schizophr Res 1996; 19: 163–70.PubMedGoogle Scholar
  27. 27.
    Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA 1998; 95: 7240–4.PubMedGoogle Scholar
  28. 28.
    LaMantia AS. Forebrain induction, retinoic acid, and vulnerability to schizophrenia: insights from molecular and genetic analysis in developing mice. Biol Psychiatry 1999; 46: 19–30.PubMedGoogle Scholar
  29. 29.
    Maynard TM, Sikich L, Lieberman JA, et al. Neural development, cell-cell signaling, and the “two-hit” hypothesis of schizophrenia. Schizophr Bull 2001; 27: 457–76.PubMedGoogle Scholar
  30. 30.
    Smith D, Wagner E, Koul O, et al. Retinoic acid synthesis for the developing telencephalon. Cereb Cortex 2001; 11: 894–905.PubMedGoogle Scholar
  31. 31.
    Reynolds GP, Abdul-Monim Z, Neill JC, et al. Calcium binding protein markers of GABA deficits in schizophrenia— postmortem studies and animal models. Neurotox Res 2004; 6: 57–61.PubMedGoogle Scholar
  32. 32.
    Mey J, McCaffery P. Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist 2004; 10: 409–21.PubMedGoogle Scholar
  33. 33.
    Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684–97, 43.PubMedGoogle Scholar
  34. 34.
    Goodman AB. Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia. Mol Psychiatry 2005; 10: 620–1.PubMedGoogle Scholar
  35. 35.
    McCaffery P, Drager UC. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dop-amine system. Proc Natl Acad Sci USA 1994; 91: 7772–6.PubMedGoogle Scholar
  36. 36.
    Galter D, Buervenich S, Carmine A, et al. ALDH1 mRNA: presence in human dopamine neurons and decreases in sub-stantia nigra in Parkinson's disease and in the ventral teg-mental area in schizophrenia. Neurobiol Dis 2003; 14: 637–47.PubMedGoogle Scholar
  37. 37.
    Buervenich S, Carmine A, Arvidsson M, et al. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am J Med Genet 2000; 96: 808–13.PubMedGoogle Scholar
  38. 38.
    Chen YH, Tsai MT, Shaw CK, et al. Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients. Am J Med Genet 2001; 105: 753–7.PubMedGoogle Scholar
  39. 39.
    McCaffery P, Lee M-O, Wagner MA, et al. Asymmetrical retinoic acid synthesis in the dorso-ventral axis of the retina. Development 1992; 115: 371–82.PubMedGoogle Scholar
  40. 40.
    McCaffery P, Dräger UC. High levels of a retinoic-acid generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci USA 1994; 91: 7772–6.PubMedGoogle Scholar
  41. 41.
    Martensen-Larsen O. Psychotic phenomena provoked by tetraethylthiuram disulfide. Q J Stud Alcohol 1951; 12: 206–16.PubMedGoogle Scholar
  42. 42.
    Fiske D. “Psychotic reaction” to tetraethylthiuram disulfide (antabuse) therapy; report of a case. J Am Med Assoc 1952; 150: 1110–1.PubMedGoogle Scholar
  43. 43.
    Liddon SC, Satran R. Disulfiram (Antabuse) psychosis. Am J Psychiatry 1967; 123: 1284–9.PubMedGoogle Scholar
  44. 44.
    Scher JM. Psychotic reaction to disulfiram. JAMA 1967; 201: 1051.PubMedGoogle Scholar
  45. 45.
    Stuller S, Bell K, Read S, et al. Antabuse psychosis. Psychiatr J Univ Ott 1983; 8: 179–80.PubMedGoogle Scholar
  46. 46.
    Murthy KK. Psychosis during disulfiram therapy for alcoholism. J Indian Med Assoc 1997; 95: 80–1.PubMedGoogle Scholar
  47. 47.
    Ceylan ME, Turkcan A, Mutlu E, et al. Manic episode with psychotic symptoms associated with high dose of disul-firam: a case report. J Clin Psychopharmacol 2007; 27: 224–5.PubMedGoogle Scholar
  48. 48.
    Quail M, Karelse RH. Disulfiram psychosis. A case report. S Afr Med J 1980; 57: 551–2.Google Scholar
  49. 49.
    Tank AW, Deitrich RA, Weiner H. Effects of induction of rat liver cytosolic aldehyde dehydrogenase on the oxidation of biogenic aldehydes. Biochem Pharmacol 1986; 35: 4563–9.PubMedGoogle Scholar
  50. 50.
    Collard F, Vertommen D, Fortpied J, et al. Identification of 3-deoxyglucosone dehydrogenase as aldehyde dehydroge-nase 1A1 (retinaldehyde dehydrogenase 1). Biochimie 2007; 89: 369–73.PubMedGoogle Scholar
  51. 51.
    McCaffery P, Wagner E, O'Neil J, et al. Dorsal and ventral retinoic territories defined by retinoic acid synthesis, breakdown and nuclear receptor expression. Mech Dev 1999; 85: 203–14.PubMedGoogle Scholar
  52. 52.
    Molotkov A, Duester G. Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid. J Biol Chem 2003; 278: 36085–90.PubMedGoogle Scholar
  53. 53.
    Jacobs FM, Smits SM, Noorlander CW, et al. Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development 2007; 134: 2673–84.PubMedGoogle Scholar
  54. 54.
    Shprintzen RJ, Goldberg R, Golding-Kushner KJ, et al. Late-onset psychosis in the velo-cardio-facial syndrome. Am J Med Genet 1992; 42: 141–2.PubMedGoogle Scholar
  55. 55.
    Chow EW, Bassett AS, Weksberg R. Velo-cardio-facial syndrome and psychotic disorders: implications for psychiatric genetics. Am J Med Genet 1994; 54: 107–12.PubMedGoogle Scholar
  56. 56.
    Gothelf D, Eliez S, Thompson T, et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 2005; 8: 1500–2.PubMedGoogle Scholar
  57. 57.
    Coberly S, Lammer E, Alashari M. Retinoic acid embryopa-thy: case report and review of literature. Pediatr Pathol Lab Med 1996; 16: 823–36.PubMedGoogle Scholar
  58. 58.
    Vermot J, Niederreither K, Garnier JM, et al. Decreased embryonic retinoic acid synthesis results in a DiGeorge syndrome phenotype in newborn mice. Proc Natl Acad Sci USA 2003; 100: 1763–8.PubMedGoogle Scholar
  59. 59.
    59 Guris DL, Duester G, Papaioannou VE, et al Dose-dependent interaction of Tbx1 and Crkl and locally aberrant RA signaling in a model of del22q11 syndrome. Dev Cell 2006; 10: 81–92.PubMedGoogle Scholar
  60. 60.
    Paylor R, Glaser B, Mupo A, et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci USA 2006; 103: 7729–34.PubMedGoogle Scholar
  61. 61.
    Ruano D, Macedo A, Soares MJ, et al. Transthyretin: no association between serum levels or gene variants and schizophrenia. J Psychiatr Res 2007; 41: 667–72.PubMedGoogle Scholar
  62. 62.
    Huang JT, Leweke FM, Oxley D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006; 3: e428.PubMedGoogle Scholar
  63. 63.
    Huang JT, Leweke FM, Tsang TM, et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE 2007; 2: e756.PubMedGoogle Scholar
  64. 64.
    Wan C, Yang Y, Li H, et al. Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res 2006; 5: 3213–6.PubMedGoogle Scholar
  65. 65.
    Feng J, Chen J, Yan J, et al. Structural variants in the retin-oid receptor genes in patients with schizophrenia and other psychiatric diseases. Am J Med Genet B Neuropsychiatr Genet 2005; 133: 50–3.Google Scholar
  66. 66.
    Ishiguro H, Okubo Y, Ohtsuki T, et al. Mutation analysis of the retinoid X receptor beta, nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence: possible haplotype association of nuclear-related receptor 1 gene to alcohol dependence. Am J Med Genet 2002; 114: 15–23.PubMedGoogle Scholar
  67. 67.
    Rioux L, Arnold SE. The expression of retinoic acid receptor alpha is increased in the granule cells of the dentate gyrus in schizophrenia. Psychiatry Res 2005; 133: 13–21.PubMedGoogle Scholar
  68. 68.
    Langlois MC, Beaudry G, Zekki H, et al. Impact of antipsy-chotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience 2001; 106: 117–28.PubMedGoogle Scholar
  69. 69.
    Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 2006; 7: 850–9.PubMedGoogle Scholar
  70. 70.
    Impagnatiello F, Guidotti AR, Pesold C, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998; 95: 15718–23.PubMedGoogle Scholar
  71. 71.
    Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57: 1061–9.PubMedGoogle Scholar
  72. 72.
    Wedenoja J, Loukola A, Tuulio-Henriksson A, et al. Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. Mol Psychiatry 2007.Google Scholar
  73. 73.
    Fatemi SH, Earle JA, McMenomy T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry 2000; 5: 654–63, 571.PubMedGoogle Scholar
  74. 74.
    Tremolizzo L, Carboni G, Ruzicka WB, et al. An epigenetic mouse model for molecular and behavioral neuropatholo-gies related to schizophrenia vulnerability. Proc Natl Acad Sci USA 2002; 99: 17095–100.PubMedGoogle Scholar
  75. 75.
    Grayson DR, Jia X, Chen Y, et al. Reelin promoter hyperm-ethylation in schizophrenia. Proc Natl Acad Sci USA 2005; 102: 9341–6.PubMedGoogle Scholar
  76. 76.
    Chen Y, Sharma RP, Costa RH, et al. On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res 2002; 30: 2930–9.PubMedGoogle Scholar
  77. 77.
    Reif A, Schmitt A, Fritzen S, et al. Neurogenesis and schizophrenia: dividing neurons in a divided mind? Eur Arch Psychiatry Clin Neurosci 2007; 257: 290–9.PubMedGoogle Scholar
  78. 78.
    Kempermann G, Krebs J, Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr Opin Psychiatry 2008; 21: 290–5.PubMedGoogle Scholar
  79. 79.
    Duan X, Chang JH, Ge S, et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007; 130: 1146–58.PubMedGoogle Scholar
  80. 80.
    Jacobs S, Lie DC, Decicco KL, et al. Retinoic acid is required early during adult neurogenesis in the dentate gyrus. Proc Natl Acad Sci USA 2006; 103: 3902–7.PubMedGoogle Scholar
  81. 81.
    Crandall J, Sakai Y, Zhang J, et al. 13-cis-retinoic acid suppresses hippocampal cell division and hippocampal-dependent learning in mice. Proc Natl Acad Sci USA 2004; 101: 5111–6.PubMedGoogle Scholar
  82. 82.
    Samad TA, Krezel W, Chambon P, et al. Regulation of dop-aminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci USA 1997; 94: 14349–54.PubMedGoogle Scholar
  83. 83.
    Wolf G. Vitamin A functions in the regulation of the dop-aminergic system in the brain and pituitary gland. Nutr Rev 1998; 56: 354–5.PubMedGoogle Scholar
  84. 84.
    Valdenaire O, Maus-Moatti M, Vincent JD, et al. Retinoic acid regulates the developmental expression of dopamine D2 receptor in rat striatal primary cultures. J Neurochem 1998; 71: 929–36.PubMedGoogle Scholar
  85. 85.
    Molotkova N, Molotkov A, Duester G. Role of retinoic acid during forebrain development begins late when Raldh3 generates retinoic acid in the ventral subventricular zone. Dev Biol 2007; 303: 601–10.PubMedGoogle Scholar
  86. 86.
    Deacon TW, Pakzaban P, Isacson O. The lateral ganglionic eminence is the origin of cells committed to striatal pheno-types: neural transplantation and developmental evidence. Brain Res 1994; 668: 211–9.PubMedGoogle Scholar
  87. 87.
    Meisenzahl EM, Schmitt GJ, Scheuerecker J, et al. The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry 2007; 19: 337–45.PubMedGoogle Scholar
  88. 88.
    Pleasure SJ, Anderson S, Hevner R, et al. Cell migration from the ganglionic eminences is required for the development of hip-pocampal GABAergic interneurons. Neuron 2000; 28: 727–40.PubMedGoogle Scholar
  89. 89.
    Wonders C, Anderson SA. Cortical interneurons and their origins. Neuroscientist 2005; 11: 199–205.PubMedGoogle Scholar
  90. 90.
    Waclaw RR, Wang B, Campbell K. The homeobox gene Gsh2 is required for retinoid production in the embryonic mouse telencephalon. Development 2004; 131: 4013–20.PubMedGoogle Scholar
  91. 91.
    Wang HF, Liu FC. Regulation of multiple dopamine signal transduction molecules by retinoids in the developing stri-atum. Neuroscience 2005; 134: 97–105.PubMedGoogle Scholar
  92. 92.
    Imai Y, Suzuki Y, Matsui T, et al. Cloning of a retinoic acid-induced gene, GT1, in the embryonal carcinoma cell line P19: neuron-specific expression in the mouse brain. Brain Res Mol Brain Res 1995; 31: 1–9.PubMedGoogle Scholar
  93. 93.
    Joober R, Benkelfat C, Toulouse A, et al. Analysis of 14 CAG repeat-containing genes in schizophrenia. Am J Med Genet 1999; 88: 694–9.PubMedGoogle Scholar
  94. 94.
    Toulouse A, Rochefort D, Roussel J, et al. Molecular cloning and characterization of human RAI1, a gene associated with schizophrenia. Genomics 2003; 82: 162–71.PubMedGoogle Scholar
  95. 95.
    Seranski P, Hoff C, Radelof U, et al. RAI1 is a novel poly-glutamine encoding gene that is deleted in Smith-Magenis syndrome patients. Gene 2001; 270: 69–76.PubMedGoogle Scholar
  96. 96.
    Slager RE, Newton TL, Vlangos CN, et al. Mutations in RAI1 associated with Smith-Magenis syndrome. Nat Genet 2003; 33: 466–8.PubMedGoogle Scholar
  97. 97.
    Girirajan S, Patel N, Slager RE, et al. How much is too much? Phenotypic consequences of Rai1 overexpression in mice. Eur J Hum Genet 2008; 16:941–54.PubMedGoogle Scholar
  98. 98.
    Middleton FA, Pato CN, Gentile KL, et al. Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. Am J Med Genet B Neuropsychiatr Genet 2005; 136: 12–25.Google Scholar
  99. 99.
    Wang YZ, Christakos S. Retinoic acid regulates the expression of the calcium binding protein, calbindin-D28K. Mol Endocrinol 1995; 9: 1510–21.PubMedGoogle Scholar
  100. 100.
    Iniguez MA, Morte B, Rodriguez-Pena A, et al. Characterization of the promoter region and flanking sequences of the neuron-specific gene RC3 (neurogranin). Brain Res Mol Brain Res 1994; 27: 205–14.PubMedGoogle Scholar
  101. 101.
    Enderlin V, Vallortigara J, Alfos S, et al. Retinoic acid reverses the PTU related decrease in neurogranin level in mice brain. J Physiol Biochem 2004; 60: 191–8.PubMedGoogle Scholar
  102. 102.
    Ruano D, Aulchenko YS, Macedo A, et al. Association of the gene encoding neurogranin with schizophrenia in males. J Psychiatr Res 2008; 42: 125–33.PubMedGoogle Scholar
  103. 103.
    Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36: 131–7.PubMedGoogle Scholar
  104. 104.
    Kalkman HO. The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther 2006; 110: 117–34.PubMedGoogle Scholar
  105. 105.
    Lopez-Carballo G, Moreno L, Masia S, et al. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem 2002; 277: 25297–304.PubMedGoogle Scholar
  106. 106.
    Bastien J, Plassat JL, Payrastre B, et al. The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells. Oncogene 2006; 25: 2040–7.PubMedGoogle Scholar
  107. 107.
    Matkovic K, Brugnoli F, Bertagnolo V, et al. The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells. Leukemia 2006; 20: 941–51.PubMedGoogle Scholar
  108. 108.
    Park E Y, Wilder ET, Chipuk JE, et al. Retinol decreases phosphatidylinositol 3-kinase activity in colon cancer cells. Mol Carcinog 2008; 47: 264–74.PubMedGoogle Scholar
  109. 109.
    Peveler R, Carson A, Rodin G. ABC of psychological medicine: depression in medical patients. BMJ 2002; 325: 149–52.PubMedGoogle Scholar
  110. 110.
    Manji HK, Drevets WC, Charney DS. The cellular neuro-biology of depression. Nat Med 2001; 7: 541–7.PubMedGoogle Scholar
  111. 111.
    Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001; 2: 343–51.PubMedGoogle Scholar
  112. 112.
    Neumeister A, Young T, Stastny J. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology (Berl) 2004; 174: 512–24.Google Scholar
  113. 113.
    Nemeroff CB. New directions in the development of anti-depressants: the interface of neurobiology and psychiatry. Hum Psychopharmacol Clin Exp 2002; 17: S13–S6.Google Scholar
  114. 114.
    Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116–27.PubMedGoogle Scholar
  115. 115.
    Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007; 10: 1089–93.PubMedGoogle Scholar
  116. 116.
    Santarelli L, Saxe M, Gross C, et al. Requirement of hip-pocampal neurogenesis for the behavioral effects of anti-depressants. Science 2003; 301: 805–9.PubMedGoogle Scholar
  117. 117.
    Vollmayr B, Mahlstedt M, Henn F. Neurogenesis and depression: what animal models tell us about the link. Eur Arch Psychiatry Clin Neurosci 2007; 257: 300–3.PubMedGoogle Scholar
  118. 118.
    Lesch KP. Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci 2004; 29: 174–84.PubMedGoogle Scholar
  119. 119.
    Zill P, Baghai TC, Zwanzger P, et al. SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 2004; 9: 1030–6.PubMedGoogle Scholar
  120. 120.
    Sklar P, Gabriel SB, McInnis MG, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutro-phic factor. Mol Psychiatry 2002; 7: 579–93.Google Scholar
  121. 121.
    Mossner R, Mikova O, Koutsilieri E, et al. Consensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression. World J Biol Psychiatry 2007; 8: 141–74.PubMedGoogle Scholar
  122. 122.
    O'Donnell J. Polar hysteria: an expression of hypervita-minosis A. Am J Ther 2004; 11: 507–16.PubMedGoogle Scholar
  123. 123.
    Muenter MD, Perry HO, Ludwig J. Chronic vitamin A intoxication in adults: Hepatic, neurologic and dermato-logic complications. Am J Med 1971; 50: 129–36.PubMedGoogle Scholar
  124. 124.
    Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin 2005; 23: 665–74.PubMedGoogle Scholar
  125. 125.
    Bremner JD, McCaffery P. The neurobiology of retinoic acid in affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 315–31.PubMedGoogle Scholar
  126. 126.
    126.Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link? J Am Acad Dermatol 2001; 45: S168–75.PubMedGoogle Scholar
  127. 127.
    Wysowski DK, Pitts M, Beitz J. Depression and suicide in patients treated with isotretinoin. N Engl J Med 2001; 344: 460.PubMedGoogle Scholar
  128. 128.
    Meyskens FLJ. Short clinical reports. J Am Acad Dermatol 1982; 6: 732–3.Google Scholar
  129. 129.
    Bremner JD, Fani N, Ashraf A, et al. Functional brain imaging alterations in acne patients treated with isotretin-oin. Am J Psychiatry 2005; 162: 983–91.PubMedGoogle Scholar
  130. 130.
    Starling J, 3rd, Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. J Drugs Dermatol 2005; 4: 690–6.PubMedGoogle Scholar
  131. 131.
    O'Reilly KC, Shumake J, Gonzalez-Lima F, et al. Chronic administration of 13-cis-retinoic acid increases depression-related behavior in mice. Neuropsychopharmacology 2006; 31: 1919–27.PubMedGoogle Scholar
  132. 132.
    Ferguson SA, Cisneros FJ, Gough B, et al. Chronic oral treatment with 13-cis-retinoic acid (isotretinoin) or all-trans-retinoic acid does not alter depression-like behaviors in rats. Toxicol Sci 2005; 87: 451–9.PubMedGoogle Scholar
  133. 133.
    Ferguson SA, Cisneros FJ, Hanig JP, et al. Oral treatment with ACCUTANE does not increase measures of anhedo-nia or depression in rats. Neurotoxicol Teratol 2007; 29: 642–51.PubMedGoogle Scholar
  134. 134.
    Ferguson SA, Berry KJ. Oral Accutane (13-cis-retinoic acid) has no effects on spatial learning and memory in male and female Sprague-Dawley rats. Neurotoxicol Teratol 2007; 29: 219–27.PubMedGoogle Scholar
  135. 135.
    Trent S, Mitchell PJ, Bailey SJ. Chronic treatment of rats with 13-cis retinoic acid changes aggressive behaviours in the resident-intruder paradigm From the Brighton Winter 2007 Meeting: Proceedings of the British Pharmacological Society at http://wwwpa2onlineorg/abstracts/Vol5Issue 2abst137Ppdf 2007
  136. 136.
    Sousa JC, Grandela C, Fernandez-Ruiz J, et al. Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem 2004; 88: 1052–8.PubMedGoogle Scholar
  137. 137.
    O'Reilly K, Bailey SJ, Lane MA. Retinoid-mediated regulation of mood: possible cellular mechanisms. Exp Biol Med 2008; 233: 251–8.Google Scholar
  138. 138.
    O'Reilly KC, Trent S, Bailey SJ, et al. 13-Cis-retinoic acid alters intracellular serotonin, increases 5-HT1A receptor, and serotonin reuptake transporter levels in vitro. Exp Biol Med 2007; 232: 1195–203.Google Scholar
  139. 139.
    Ferguson SA, Cisneros FJ, Gough BJ, et al. Four weeks of oral isotretinoin treatment causes few signs of general tox-icity in male and female Sprague-Dawley rats. Food Chem Toxicol 2005; 43: 1289–96.PubMedGoogle Scholar
  140. 140.
    Matsuoka I, Kumagai M, Kurihara K. Differential and coordinated regulation of expression of norepinephrine transporter in catecholaminergic cells in culture. Brain Res 1997; 776: 181–8.PubMedGoogle Scholar
  141. 141.
    Sodja C, Fang H, Dasgupta T, et al. Identification of functional dopamine receptors in human teratocarcinoma NT2 cells. Brain Res Mol Brain Res 2002; 99: 83–91.PubMedGoogle Scholar
  142. 142.
    Ishikawa J, Sutoh C, Ishikawa A, et al. 13-cis-retinoic acid alters the cellular morphology of slice-cultured serotonergic neurons in the rat. Eur J Neurosci 2008; 27: 2363–72.PubMedGoogle Scholar
  143. 143.
    Liu Y, Kagechika H, Ishikawa J, et al. Effects of retinoic acids on the dendritic morphology of cultured hippocam-pal neurons. J Neurochem 2008; 106:591–602.Google Scholar
  144. 144.
    Lucarelli E, Kaplan DR, Thiele CJ. Selective regulation of TrkA and TrkB receptors by retinoic acid and interferon-gamma in human neuroblastoma cell lines. J Biol Chem 1995; 270: 24725–31.PubMedGoogle Scholar
  145. 145.
    Salvatore AM, Cozzolino M, Gargano N, et al. Neuronal differentiation of P19 embryonal cells exhibits cell-specific regulation of neurotrophin receptors. Neuroreport 1995; 6: 873–7.PubMedGoogle Scholar
  146. 146.
    Scheibe RJ, Wagner JA. Retinoic acid regulates both expression of the nerve growth factor receptor and sensitivity to nerve growth factor. J Biol Chem 1992; 267: 17611–6.PubMedGoogle Scholar
  147. 147.
    Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1103–12.PubMedGoogle Scholar
  148. 148.
    Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psycho-pharmacol 2005; 19: 59–65.Google Scholar
  149. 149.
    Jasim ZF, McKenna KE. Vitamin B12 and folate deficiency anaemia associated with isotretinoin treatment for acne. Clin Exp Dermatol 2006; 31: 599.PubMedGoogle Scholar
  150. 150.
    Schulpis KH, Karikas GA, Georgala S, et al. Elevated plasma homocysteine levels in patients on isotretinoin therapy for cystic acne. Int J Dermatol 2001; 40: 33–6.PubMedGoogle Scholar
  151. 151.
    Chanson A, Cardinault N, Rock E, et al. Decreased plasma folate concentration in young and elderly healthy subjects after a short-term supplementation with isotretinoin. J Eur Acad Dermatol Venereol 2008; 22: 94–100.PubMedGoogle Scholar
  152. 152.
    Ozias MK, Schalinske KL. All-trans-retinoic acid rapidly induces glycine N-methyltransferase in a dose-dependent manner and reduces circulating methionine and homo-cysteine levels in rats. J Nutr 2003; 133: 4090–4.PubMedGoogle Scholar
  153. 153.
    Rowling MJ, McMullen MH, Schalinske KL. Vitamin A and its derivatives induce hepatic glycine N-methyltransferase and hypomethylation of DNA in rats. J Nutr 2002; 132: 365–9.PubMedGoogle Scholar
  154. 154.
    DeLong R. Autism and familial major mood disorder: are they related? J Neuropsychiatry Clin Neurosci 2004; 16: 199–213.PubMedGoogle Scholar
  155. 155.
    Leyfer OT, Folstein SE, Bacalman S, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 2006; 36: 849–61.PubMedGoogle Scholar
  156. 156.
    Spence SJ. The genetics of autism. Semin Pediatr Neurol 2004; 11: 196–204.PubMedGoogle Scholar
  157. 157.
    Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007; 17: 434–47.PubMedGoogle Scholar
  158. 158.
    London E, Etzel RA. The environment as an etiologic factor in autism: a new direction for research. Environ Health Perspect 2000; 108: 401–4.PubMedGoogle Scholar
  159. 159.
    Hashimoto T, Tayama M, Miyazaki M, et al. Brainstem and cerebellar vermis involvement in autistic children. J Child Neurol 1993; 8: 149–53.PubMedGoogle Scholar
  160. 160.
    Makori N, Peterson PE, Hendrickx AG. 13-cis-retinoic acid causes patterning defects in the early embryonic rostral hindbrain and abnormal development of the cerebellum in the macaque. Teratology 2001; 63: 65–76.PubMedGoogle Scholar
  161. 161.
    Hashimoto T, Tayama M, Murakawa K, et al. Development of the brainstem and cerebellum in autistic patients. J Autism Dev Disord 1995; 25: 1–18.PubMedGoogle Scholar
  162. 162.
    Rodier PM, Ingram JL, Tisdale B, et al. Linking etiologies in humans and animal models: studies of autism. Reprod Toxicol 1997; 11: 417–22.PubMedGoogle Scholar
  163. 163.
    Holson RR, Cogan JE, Adams J. Gestational retinoic acid exposure in the rat: effects of sex, strain and exposure period. Neurotoxicol Teratol 2001; 23: 147–56.PubMedGoogle Scholar
  164. 164.
    Yamamoto M, Fujinuma M, Hirano S, et al. Retinoic acid influences the development of the inferior olivary nucleus in the rodent. Dev Biol 2005; 280: 421–33.PubMedGoogle Scholar
  165. 165.
    McCaffery P, Deutsch CK. Macrocephaly and the control of brain growth in autistic disorders. Prog Neurobiol 2005; 77: 38–56.PubMedGoogle Scholar
  166. 166.
    Christianson AL, Chesler N, Kromberg JG. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 1994; 36: 361–9.PubMedGoogle Scholar
  167. 167.
    Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Dev Med Child Neurol 1997; 39: 632–4.PubMedGoogle Scholar
  168. 168.
    Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37: 489–97.PubMedGoogle Scholar
  169. 169.
    Williams G, King J, Cunningham M, et al. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001; 43: 202–6.PubMedGoogle Scholar
  170. 170.
    Rasalam AD, Hailey H, Williams JH, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 2005; 47: 551–5.PubMedGoogle Scholar
  171. 171.
    Rodier PM, Ingram JL, Tisdale B, et al. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J Comp Neurol 1996; 370: 247–61.PubMedGoogle Scholar
  172. 172.
    Ingram JL, Peckham SM, Tisdale B, et al. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 2000; 22: 319–24.PubMedGoogle Scholar
  173. 173.
    Narita N, Kato M, Tazoe M, et al. Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 2002; 52: 576–9.PubMedGoogle Scholar
  174. 174.
    Schneider T, Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005; 30: 80–9.PubMedGoogle Scholar
  175. 175.
    Kultima K, Nystrom AM, Scholz B, et al. Valproic acid teratogenicity: a toxicogenomics approach. Environ Health Perspect 2004; 112: 1225–35.PubMedGoogle Scholar
  176. 176.
    Epping MT, Wang L, Plumb JA, et al. A functional genetic screen identifies retinoic acid signaling as a target of his-tone deacetylase inhibitors. Proc Natl Acad Sci USA 2007; 104: 17777–82.PubMedGoogle Scholar
  177. 177.
    Ross SA, McCaffery PJ, Drager UC, et al. Retinoids in embryonal development. Physiol Rev 2000; 80: 1021–54.PubMedGoogle Scholar
  178. 178.
    Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis retin-oic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68: 397–406.PubMedGoogle Scholar
  179. 179.
    Wolf G. Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X receptor? Nutr Rev 2006; 64: 532–8.PubMedGoogle Scholar
  180. 180.
    Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841–50.PubMedGoogle Scholar
  181. 181.
    Ahuja HS, Szanto A, Nagy L, et al. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J Biol Regul Homeost Agents 2003; 17: 29–45.PubMedGoogle Scholar
  182. 182.
    McCaffery P, Drager UC. Hot spots of retinoic acid synthesis in the developing spinal cord. Proc Natl Acad Sci USA 1994; 91: 7194–7.PubMedGoogle Scholar
  183. 183.
    Gampe RT, Jr., Montana VG, Lambert MH, et al. Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes Dev 2000; 14: 2229–41.PubMedGoogle Scholar
  184. 184.
    Egea PF, Rochel N, Birck C, et al. Effects of ligand binding on the association properties and conformation in solution of retinoic acid receptors RXR and RAR. J Mol Biol 2001; 307: 557–76.PubMedGoogle Scholar
  185. 185.
    oehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apop-tosis in leukemia cells. J Med Chem 1995; 38: 3146–55.Google Scholar
  186. 186.
    Lerner V, Miodownik C, Gibel A, et al. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin Neuropharmacol 2008; 31: 25–33.PubMedGoogle Scholar
  187. 187.
    Sharma RP. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr Res 2005; 72: 79–90.PubMedGoogle Scholar
  188. 188.
    Craddock N, O'Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 2006; 32: 9–16.PubMedGoogle Scholar
  189. 189.
    Javitt DC, Spencer KM, Thaker GK, et al. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008; 7: 68–83.PubMedGoogle Scholar
  190. 190.
    Mark M, Ghyselinck NB, Wendling O, et al. A genetic dissection of the retinoid signalling pathway in the mouse. Proc Nutr Soc 1999; 58: 609–13.PubMedGoogle Scholar
  191. 191.
    Quadro L, Blaner WS, Salchow DJ, et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. EMBO J 1999; 18: 4633–44.PubMedGoogle Scholar
  192. 192.
    Niederreither K, Subbarayan V, Dolle P, et al. Embryonic retinoic acid synthesis is essential for early mouse postimplantation development. Nat Genet 1999; 21: 444–8.PubMedGoogle Scholar
  193. 193.
    Dupe V, Matt N, Garnier JM, et al. A newborn lethal defect due to inactivation of retinaldehyde dehydrogenase type 3 is prevented by maternal retinoic acid treatment. Proc Natl Acad Sci USA 2003; 100: 14036–41.PubMedGoogle Scholar
  194. 194.
    Abu-Abed S, Dolle P, Metzger D, et al. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev 2001; 15: 226–40.PubMedGoogle Scholar
  195. 195.
    Sakai Y, Meno C, Fujii H, et al. The retinoic acid-inactivating enzyme CYP26 is essential for establishing an uneven distribution of retinoic acid along the anterio-posterior axis within the mouse embryo. Genes Dev 2001; 15: 213–25.PubMedGoogle Scholar
  196. 196.
    Yashiro K, Zhao X, Uehara M, et al. Regulation of retinoic acid distribution is required for proximodistal patterning and outgrowth of the developing mouse limb. Dev Cell 2004; 6: 411–22.PubMedGoogle Scholar
  197. 197.
    Sullivan GM, Mann JJ, Oquendo MA, et al. Low cerebro-spinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry 2006; 60: 500–6.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Sarah J. Bailey
    • 1
  • Peter J. McCaffery
    • 2
  1. 1.Department of Pharmacy and PharmacologyUniversity of BathClaverton DownUK
  2. 2.University of Aberdeen, Institute of Medical SciencesForesterhillUK

Personalised recommendations